Therapeutic efficacy of hepatic resection versus radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a propensity score matching study

肝切除术与射频消融术治疗符合米兰标准的复发性肝细胞癌的疗效比较:一项倾向评分匹配研究

阅读:2

Abstract

BACKGROUND: Hepatic resection(HR) and radiofrequency ablation(RFA) are widely used for recurrent hepatocellular carcinoma(RHCC), yet their therapeutic efficacy remains debated. This study aimed to compare outcomes of HR versus RFA in RHCC patients within Milan Criteria. METHODS: This was a retrospective single-center study of patients with HCC recurrence after initial radical hepatectomy for primary liver cancer, meeting Milan criteria for recurrence. Patients underwent HR (n = 128) or RFA (n = 134) at West China Hospital of Sichuan University between January 2015 and August 2019. The final follow-up date for this study was August 31, 2022. Propensity score matching (1:1 ratio) was applied to balance baseline characteristics. Clinical outcomes were analyzed before and after matching. RESULTS: Before matching, the hepatic resection group demonstrated significantly higher 1-, 3-, and 5-year recurrence-free survival rates compared to the radiofrequency ablation group (67.2%, 41.7%, 31.3% vs. 55.2%, 26.5%, 17.3%; P = 0.007), but overall survival showed no significant difference (99.2%, 80.0%, 63.9% vs. 94.2%, 72.6%, 42.4%; P = 0.064). After matching, recurrence-free survival remained higher in the hepatic resection group (71.5%, 44.9%, 36.1% vs. 57.8%, 29.9%, 17.0%; P = 0.013), while overall survival differences remained nonsignificant (97.8%, 78.1%, 58.5% vs. 91.5%, 74.9%, 42.6%; P = 0.203). Hepatic resection was associated with higher hospitalization costs, blood loss, longer hospital stays, and more complications (all P < 0.001). Subgroup analysis revealed no significant differences in recurrence-free or overall survival when the recurrence interval was ≤ 24 months. Multivariate analysis identified recurrence interval ≤ 24 months and radiofrequency ablation as independent risk factors for tumor recurrence, while recurrence interval ≤ 24 months or preoperative alpha-fetoprotein > 200 ng/ml were risk factors affecting overall survival. CONCLUSION: For recurrent hepatocellular carcinoma within Milan Criteria, while hepatic resection improved recurrence-free survival, overall survival did not differ significantly between resection and RFA. RFA may be considered for selected high-risk surgical patients, acknowledging its higher recurrence potential.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。